Paper Details

  1. Home
  2. Paper Details

Treatment of essential thrombocythemia in Europe: a prospective long-term observational study of 3649 high-risk patients in the Evaluation of Anagrelide Efficacy and Long-term Safety study.

Author: AchenbachHeinrich, BessesCarlos, BirgegårdGunnar, GriesshammerMartin, GugliottaLuigi, HamdaniMohamed, HarrisonClaire N, KiladjianJean-Jacques, WuJingyang

Clinical Trial, Phase IVPost-marketing surveillance. Monitors long-term safety/efficacy after approval.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Anagrelide is a medication for essential thrombocythemia. This study evaluated its long-term safety and efficacy in a large cohort of patients. The study found that anagrelide was associated with a lower risk of thrombosis compared to other cytoreductive therapies, but it was also more commonly associated with hemorrhage.
Paper Details　
Original Abstract of the Article :
Evaluation of Anagrelide (Xagrid<sup>&#174;</sup>) Efficacy and Long-term Safety, a phase IV, prospective, non-interventional study performed in 13 European countries enrolled high-risk essential thrombocythemia patients treated with cytoreductive therapy. The primary objectives were safety and preg...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5777190/

データ提供：米国国立医学図書館（NLM）

Essential Thrombocythemia: A Long-Term Study of Anagrelide

This study provides long-term data on the safety and efficacy of anagrelide, a drug used to treat essential thrombocythemia, a rare blood disorder. The study, involving 3649 high-risk patients from 13 European countries, followed patients receiving anagrelide or other cytoreductive therapies. The study focused on the long-term safety of anagrelide, particularly pregnancy outcomes and the occurrence of various events like thrombosis and hemorrhage.

Long-Term Safety of Anagrelide in Essential Thrombocythemia

The study provides valuable insights into the long-term safety of anagrelide, showing comparable effectiveness to other cytoreductive therapies while demonstrating a higher rate of hemorrhage, particularly in patients receiving anti-aggregatory therapy or those with myelofibrosis. The study identifies risk factors for thrombosis and transformation, encouraging careful monitoring and individualized treatment approaches.

Navigating the Shifting Sands of Thrombocythemia Treatment

This study, like a map guiding us through the shifting sands of thrombocythemia treatment, provides valuable insights into the long-term safety and efficacy of anagrelide. While anagrelide offers potential benefits, the study emphasizes the importance of careful monitoring, personalized treatment plans, and awareness of potential risks. It highlights the need for ongoing research to refine our understanding of this complex condition and optimize treatment strategies.

Dr.Camel's Conclusion

This extensive study offers valuable long-term data on the safety and efficacy of anagrelide in treating essential thrombocythemia, providing crucial information for clinicians and patients. The study highlights the importance of personalized treatment approaches, careful monitoring, and ongoing research to further refine our understanding and management of this challenging blood disorder.

Date :
  1. Date Completed 2019-07-24
  2. Date Revised 2019-07-24
Further Info :

Pubmed ID

29079600

DOI: Digital Object Identifier

PMC5777190

Related Literature

Article Analysis
・Effects of anagrelide
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.